STAT

Opinion: The White House’s about-face on drug rebates is a loss for public health

None of the $166 billion in discounts that pharmacy benefit managers get from pharmaceutical companies is used to reduce patients' out-of-pocket costs when they need medicines.
Source: BRENDAN SMIALOWSKI/AFP/Getty Images

Even in the complicated ecosystem of drug pricing, one fact stands out: $166 billion in discounts from pharmaceutical companies go directly into the coffers of pharmacy benefit managers. That’s 37% of our nation’s entire expense on drugs.

Not a single dollar of that largesse is used to reduce patients’ out-of-pocket costs when they need medicines. So when the White House to change the dynamic by banning many rebates drug companies pay to pharmacy benefit managers under Medicare, policy experts applauded. That, the victim of intense lobbying and general ignorance. Who loses? Patients. Who wins? The status quo.

You're reading a preview, sign up to read more.

More from STAT

STAT7 min readTech
One Health Care Startup At A Time, This Venture Capitalist Wants To Harness The Investing Power Of Women
“If women want specific companies in the world that address their needs, the only way to do that is for women to become the investors."
STAT4 min readSociety
Opinion: Bringing Transparency To The Notion Of Price Transparency
Transparency is not just a goal. It's also an ethic. Organizations involved in price transparency initiatives should be transparent in the ways appropriate to them.
STAT1 min read
Listen: The Serious Side Of Spit Kits, How BiTEs Leave A Mark, & Sarepta’s Sluggish Study
Is anything too weighty to be explained over the internet? Can a new spin on old technology outfox CAR-T? And does that controversial drug even work? We discuss all that and more on the latest episode of “The Readout LOUD,” STAT’s biotech podcast. Fi